These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
32. Incidence of resistance in a double-blind study comparing lopinavir/ritonavir plus stavudine and lamivudine to nelfinavir plus stavudine and lamivudine. Kempf DJ; King MS; Bernstein B; Cernohous P; Bauer E; Moseley J; Gu K; Hsu A; Brun S; Sun E J Infect Dis; 2004 Jan; 189(1):51-60. PubMed ID: 14702153 [TBL] [Abstract][Full Text] [Related]
33. Recent FDA approvals and changes. AIDS Patient Care STDS; 2011 Feb; 25(2):124-5. PubMed ID: 21370547 [No Abstract] [Full Text] [Related]
34. FDA notifications. FDA gives tentative approval for stavudine, lamivudine & nevirapine tablet. AIDS Alert; 2009 Sep; 24(9):105-6. PubMed ID: 19938312 [No Abstract] [Full Text] [Related]
35. Key clinical trials of non-nucleoside reverse transcriptase inhibitors in the treatment of chronic HIV-1 infection in adults. Williams I J HIV Ther; 2008 Mar; 13(1):19-23. PubMed ID: 18953269 [No Abstract] [Full Text] [Related]
36. WHO hopes 3-by-5 plan will reverse Africa's HIV/AIDS epidemic. Fleck F Bull World Health Organ; 2004 Jan; 82(1):77-8. PubMed ID: 15106303 [No Abstract] [Full Text] [Related]
37. The effects of discontinuing stavudine therapy on clinical and metabolic abnormalities in patients suffering from lipodystrophy. Saint-Marc T; Touraine JL AIDS; 1999 Oct; 13(15):2188-9. PubMed ID: 10546885 [No Abstract] [Full Text] [Related]
38. d4T and lactic acidosis with neuromuscular weakness: FDA warning. AIDS Treat News; 2002 Mar; (378):5-6. PubMed ID: 11965919 [No Abstract] [Full Text] [Related]
39. Symptomatic hyperlactatemia associated with nucleoside analogue reverse-transcriptase inhibitor use in HIV-infected patients: a report of 24 cases in a resource-limited setting (Uganda). Songa PM; Castelnuovo B; Mugasha EB; Ocama P; Kambugu A Clin Infect Dis; 2007 Aug; 45(4):514-7. PubMed ID: 17638205 [TBL] [Abstract][Full Text] [Related]
40. Alternation of antiretroviral drug regimens for HIV infection. Efficacy, safety and tolerability at week 96 of the Swatch Study. Negredo E; Paredes R; Peraire J; Pedrol E; Côté H; Gel S; Fumoz CR; Ruiz L; Abril V; Rodriguez de Castro E; Ochoa C; Martinez-Picado J; Montaner J; Rey-Joly C; Clotet B; Antivir Ther; 2004 Dec; 9(6):889-93. PubMed ID: 15651747 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]